Liquidia (LQDA) Capital Expenditures (2020 - 2026)
Liquidia's (LQDA) quarterly Capital Expenditures came in at $6.6 million in Q1 2026, up 42.43% year-on-year from $4.6 million in Q1 2025, and up 14735.56% quarter-over-quarter from -$45000.0 in Q4 2025.
Liquidia (LQDA) Capital Expenditures (2020 - 2026) Analysis & Trends
Liquidia's Capital Expenditures history runs 7 years deep, the most recent figure standing at $6.6 million for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 42.43% year-over-year to $6.6 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 4.13% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 972.86% from the prior year.
- Capital Expenditures grew to $6.6 million in Q1 2026 per LQDA's latest filing, from -$45000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $6.6 million in Q1 2026 and bottomed at -$3.5 million in Q4 2024.
- The 5-year median for Capital Expenditures is $243000.0 (2023), against an average of $643000.0.
- Across the five-year window, Capital Expenditures soared 9250.0% in 2023 and sank 2029.61% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $491000.0 in 2022, then tumbled by 58.04% to $206000.0 in 2023, then sank by 1775.24% to -$3.5 million in 2024, then surged by 98.7% to -$45000.0 in 2025, then soared by 14735.56% to $6.6 million in 2026.
- Per Business Quant, the three latest LQDA Capital Expenditures figures stand at $6.6 million (Q1 2026), -$45000.0 (Q4 2025), and $911000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 6.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.59 Mn |
| Mar 31, 2026 | 6.59 Mn |
| Dec 31, 2025 | -45,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Sep 30, 2025 | 911,000.00 |
| Sep 30, 2025 | 911,000.00 |
| Jun 30, 2025 | -3.24 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | 4.62 Mn |
| Mar 31, 2025 | 4.62 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | 3.03 Mn |
| Sep 30, 2024 | 3.03 Mn |
| Jun 30, 2024 | -152,000.00 |
| Jun 30, 2024 | -152,000.00 |
| Mar 31, 2024 | 786,000.00 |
| Mar 31, 2024 | 786,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Dec 31, 2023 | 206,000.00 |